Bausch + Lomb - BLCO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $19.50
  • Forecasted Upside: 31.31%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$14.85
▲ +0.21 (1.43%)

This chart shows the closing price for BLCO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bausch + Lomb Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLCO

Analyst Price Target is $19.50
▲ +31.31% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Bausch + Lomb in the last 3 months. The average price target is $19.50, with a high forecast of $25.00 and a low forecast of $16.00. The average price target represents a 31.31% upside from the last price of $14.85.

This chart shows the closing price for BLCO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Bausch + Lomb. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$20.00 ➝ $18.00Low
4/4/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$16.50 ➝ $17.00Low
2/26/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$17.00 ➝ $18.00Low
2/22/2024EvercoreLower TargetIn-Line$17.00 ➝ $16.50Low
2/22/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$21.00 ➝ $23.00Low
1/4/2024Evercore ISIDowngradeOutperform ➝ In-Line$19.00 ➝ $17.00Low
12/29/2023Royal Bank of CanadaSet TargetOutperform$20.00Low
12/12/2023CitigroupLower TargetBuy$23.00 ➝ $21.00Low
12/12/2023Stifel NicolausInitiated CoverageHold$16.00Low
12/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00Low
11/28/2023BarclaysLower TargetEqual Weight$19.00 ➝ $17.00Low
10/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $18.50Low
10/6/2023HC WainwrightLower TargetBuy ➝ Buy$22.00 ➝ $21.00Low
10/3/2023Evercore ISIInitiated CoverageOutperform$20.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$22.00Low
8/3/2023Jefferies Financial GroupBoost TargetBuy$22.00 ➝ $25.00Low
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$20.00Low
8/3/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$18.00 ➝ $19.00Low
7/24/2023Royal Bank of CanadaBoost TargetOutperform$20.00 ➝ $21.00Low
7/10/2023CitigroupBoost Target$22.00 ➝ $23.00Low
7/3/2023Bank of AmericaBoost Target$19.00 ➝ $23.00Low
5/19/2023HC WainwrightBoost Target$19.00 ➝ $22.00Low
5/5/2023HC WainwrightLower Target$21.00 ➝ $19.00Low
5/5/2023BarclaysBoost Target$17.00 ➝ $18.00Low
3/23/2023HC WainwrightReiterated RatingBuy$21.00Low
3/9/2023Needham & Company LLCInitiated CoverageHoldLow
2/24/2023HC WainwrightBoost TargetBuy$20.00 ➝ $21.00Low
2/23/2023Deutsche Bank AktiengesellschaftBoost Target$16.00 ➝ $18.00Low
2/23/2023JPMorgan Chase & Co.Boost TargetNeutral$15.00 ➝ $17.00Low
2/23/2023Royal Bank of CanadaReiterated RatingOutperform$20.00Low
2/23/2023Morgan StanleyBoost TargetEqual Weight$18.00 ➝ $20.00Low
2/15/2023Royal Bank of CanadaBoost TargetOutperform$17.00 ➝ $20.00Low
2/2/2023HC WainwrightReiterated RatingBuy$20.00Low
12/21/2022BarclaysInitiated CoverageEqual Weight$17.00Low
11/23/2022The Goldman Sachs GroupLower TargetNeutral$19.00 ➝ $17.00Low
11/3/2022Royal Bank of CanadaLower TargetOutperform$18.00 ➝ $17.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$16.00 ➝ $15.00Low
11/3/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $18.00Low
11/3/2022HC WainwrightLower TargetBuy$21.00 ➝ $20.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00Low
9/12/2022HC WainwrightInitiated CoverageBuy$21.00Low
8/30/2022The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$22.00 ➝ $19.00Low
8/16/2022The Goldman Sachs GroupLower TargetNeutral$22.00 ➝ $19.00Low
7/31/2022Royal Bank of CanadaLower TargetOutperform$22.00 ➝ $18.00Low
7/26/2022Royal Bank of CanadaReiterated RatingInitiatesLow
7/25/2022Royal Bank of CanadaInitiated CoverageOutperform$22.00Low
6/24/2022Evercore ISIInitiated CoverageOutperform$21.00Low
6/9/2022Morgan StanleyLower TargetEqual Weight$22.00 ➝ $20.00Medium
6/6/2022CitigroupInitiated CoverageBuy$22.00High
5/31/2022Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$25.00Medium
5/31/2022Bank of AmericaInitiated CoverageBuyMedium
5/31/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$19.00Medium
5/31/2022JPMorgan Chase & Co.Initiated CoverageNeutral$20.00Medium
5/31/2022GuggenheimInitiated CoverageBuy$24.00Medium
5/31/2022Wells Fargo & CompanyInitiated CoverageOverweight$23.00Medium
5/31/2022Morgan StanleyInitiated CoverageEqual Weight$22.00Medium
5/31/2022The Goldman Sachs GroupInitiated CoverageNeutral$22.00Medium
5/11/2022CowenInitiated CoverageOutperform$35.00Medium
5/11/2022CowenInitiated CoverageOutperform$35.00Medium
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/27/2023
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 11 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/24/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Bausch + Lomb logo
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
Read More

Today's Range

Now: $14.85
Low: $14.70
High: $15.01

50 Day Range

MA: $15.92
Low: $14.06
High: $17.60

52 Week Range

Now: $14.85
Low: $13.62
High: $21.95

Volume

352,033 shs

Average Volume

479,244 shs

Market Capitalization

$5.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch + Lomb?

The following Wall Street analysts have issued research reports on Bausch + Lomb in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Evercore Inc., Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Royal Bank of Canada, Stifel Nicolaus, and Wells Fargo & Company.
View the latest analyst ratings for BLCO.

What is the current price target for Bausch + Lomb?

11 Wall Street analysts have set twelve-month price targets for Bausch + Lomb in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 31.3%. Jefferies Financial Group Inc. has the highest price target set, predicting BLCO will reach $25.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $16.00 for Bausch + Lomb in the next year.
View the latest price targets for BLCO.

What is the current consensus analyst rating for Bausch + Lomb?

Bausch + Lomb currently has 5 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BLCO.

What other companies compete with Bausch + Lomb?

How do I contact Bausch + Lomb's investor relations team?

The company's listed phone number is 905-695-7700. The official website for Bausch + Lomb is www.bausch.com. Learn More about contacing Bausch + Lomb investor relations.